# CEOå„ªå…ˆåº¦åˆ†é¡å®Œå…¨ç‰ˆ - 608å€‹ã®ä¸è¶³ã‚¯ãƒ©ã‚¹

**ä½œæˆæ—¥æ™‚**: 2025-07-02 17:38  
**ä½œæˆè€…**: CEO  
**åˆ†é¡åŸºæº–**: æ©Ÿèƒ½çš„é‡è¦æ€§Ã—ä½¿ç”¨é »åº¦Ã—æ•™è‚²çš„ä¾¡å€¤

---

## ğŸ“Š åˆ†é¡ã‚µãƒãƒªãƒ¼

| å„ªå…ˆåº¦ | åˆ†é¡ | ã‚¯ãƒ©ã‚¹æ•° | å®Ÿè£…æ™‚é–“ |
|--------|------|----------|----------|
| P0 | æœ€å„ªå…ˆï¼ˆåŸºæœ¬æ§‹é€ ï¼‰ | 35å€‹ | 30åˆ† |
| P1 | é«˜å„ªå…ˆï¼ˆå­¦ç¿’ã‚·ã‚¹ãƒ†ãƒ ï¼‰ | 85å€‹ | 120åˆ† |
| P2 | ä¸­å„ªå…ˆï¼ˆè–¬å­¦å°‚é–€ï¼‰ | 220å€‹ | 90åˆ† |
| P3 | ä½å„ªå…ˆï¼ˆè£…é£¾çš„ï¼‰ | 268å€‹ | 90åˆ† |
| **åˆè¨ˆ** | | **608å€‹** | **330åˆ†** |

---

## ğŸ”´ P0: æœ€å„ªå…ˆã‚¯ãƒ©ã‚¹ï¼ˆ35å€‹ï¼‰

### åŸºæœ¬æ§‹é€ ï¼ˆ10å€‹ï¼‰
```css
.basic-info-card        /* è–¬å­¦ç”Ÿå‘ã‘åŸºæœ¬æƒ…å ±ã‚«ãƒ¼ãƒ‰ */
.drug-name-display      /* è–¬å‰¤åè¡¨ç¤ºï¼ˆå®šç¾©æ¸ˆã¿ã€è¦ç¢ºèªï¼‰ */
.brand-name            /* ãƒ–ãƒ©ãƒ³ãƒ‰å */
.generic-name          /* ä¸€èˆ¬å */
.classification-badges /* åˆ†é¡ãƒãƒƒã‚¸ */
.drug-class-badge      /* è–¬åŠ¹åˆ†é¡ãƒãƒƒã‚¸ */
.first-choice-badge    /* ç¬¬ä¸€é¸æŠè–¬ãƒãƒƒã‚¸ */
.main-indications      /* ä¸»ãªé©å¿œç—‡ */
.indication-list       /* é©å¿œç—‡ãƒªã‚¹ãƒˆ */
.primary               /* ä¸»è¦é©å¿œ */
```

### ã‚µãƒãƒªãƒ¼é–¢é€£ï¼ˆ8å€‹ï¼‰
```css
.quick-summary-student  /* 30ç§’ã‚µãƒãƒªãƒ¼ */
.summary-grid          /* ã‚µãƒãƒªãƒ¼ã‚°ãƒªãƒƒãƒ‰ */
.summary-item          /* ã‚µãƒãƒªãƒ¼é …ç›® */
.fic-status            /* FICï¼ˆFirst in Classï¼‰ã‚¹ãƒ†ãƒ¼ã‚¿ã‚¹ */
.fic-badge             /* FICãƒãƒƒã‚¸ */
.why-developed         /* ãªãœé–‹ç™ºã•ã‚ŒãŸã‹ */
.clinical-use          /* è‡¨åºŠä½¿ç”¨ */
.vs-similar            /* ä»–è–¬ã¨ã®æ¯”è¼ƒ */
```

### FAQé–¢é€£ï¼ˆ7å€‹ï¼‰
```css
.student-faq-section   /* è–¬å­¦ç”ŸFAQ */
.student-questions     /* å­¦ç”Ÿã®è³ªå• */
.faq-note             /* FAQæ³¨è¨˜ */
.level-guide          /* ãƒ¬ãƒ™ãƒ«ã‚¬ã‚¤ãƒ‰ */
.star-rating          /* å›½è©¦é »å‡ºåº¦ï¼ˆâ˜…è¡¨ç¤ºï¼‰ */
.question-priority    /* è³ªå•å„ªå…ˆåº¦ */
.answer-depth        /* å›ç­”æ·±åº¦ */
```

### å‡¦æ–¹é–¢é€£ï¼ˆ5å€‹ï¼‰
```css
.prescription-examples /* å‡¦æ–¹ä¾‹ */
.rx-example           /* å‡¦æ–¹ä¾‹ãƒ•ã‚©ãƒ¼ãƒãƒƒãƒˆ */
.rx-format            /* å‡¦æ–¹æ›¸å¼ */
.dosage-note          /* ç”¨é‡æ³¨è¨˜ */
.prescription-pattern /* å‡¦æ–¹ãƒ‘ã‚¿ãƒ¼ãƒ³ï¼ˆå®šç¾©æ¸ˆã¿ã€è¦ç¢ºèªï¼‰ */
```

### ãƒ¬ãƒ™ãƒ«åˆ¶å¾¡ï¼ˆ5å€‹ï¼‰
```css
.level-indicator      /* ãƒ¬ãƒ™ãƒ«ã‚¤ãƒ³ã‚¸ã‚±ãƒ¼ã‚¿ãƒ¼ */
.level-indicator-inner /* ãƒ¬ãƒ™ãƒ«ã‚¤ãƒ³ã‚¸ã‚±ãƒ¼ã‚¿ãƒ¼å†…éƒ¨ */
.level-btn            /* ãƒ¬ãƒ™ãƒ«ãƒœã‚¿ãƒ³ */
.active               /* ã‚¢ã‚¯ãƒ†ã‚£ãƒ–çŠ¶æ…‹ */
.next-level-prompt    /* æ¬¡ãƒ¬ãƒ™ãƒ«ã¸ã®èª˜å° */
```

---

## ğŸŸ¡ P1: é«˜å„ªå…ˆã‚¯ãƒ©ã‚¹ï¼ˆ85å€‹ï¼‰

### 3æ®µéšå­¦ç¿’ã‚·ã‚¹ãƒ†ãƒ ï¼ˆ20å€‹ï¼‰
```css
.level-1-content      /* è–¬å­¦ç”Ÿãƒ¬ãƒ™ãƒ«ï¼ˆå®šç¾©æ¸ˆã¿ã€è¦æ‹¡å¼µï¼‰ */
.level-2-content      /* å®Ÿç¿’ç”Ÿãƒ¬ãƒ™ãƒ«ï¼ˆå®šç¾©æ¸ˆã¿ã€è¦æ‹¡å¼µï¼‰ */
.level-3-content      /* ç ”ä¿®åŒ»ãƒ¬ãƒ™ãƒ«ï¼ˆå®šç¾©æ¸ˆã¿ã€è¦æ‹¡å¼µï¼‰ */
.intermediate-level   /* ä¸­ç´šãƒ¬ãƒ™ãƒ« */
.advanced-level       /* ä¸Šç´šãƒ¬ãƒ™ãƒ« */
.level-guide-section  /* ãƒ¬ãƒ™ãƒ«ã‚¬ã‚¤ãƒ‰ã‚»ã‚¯ã‚·ãƒ§ãƒ³ */
.learning-progress    /* å­¦ç¿’é€²æ— */
.mastery-indicator    /* ç¿’å¾—åº¦ã‚¤ãƒ³ã‚¸ã‚±ãƒ¼ã‚¿ãƒ¼ */
.competency-level     /* èƒ½åŠ›ãƒ¬ãƒ™ãƒ« */
.skill-progression    /* ã‚¹ã‚­ãƒ«é€²è¡Œ */
```

### å®Ÿè·µãƒ»è‡¨åºŠé–¢é€£ï¼ˆ25å€‹ï¼‰
```css
.practice-point       /* å®Ÿè·µãƒã‚¤ãƒ³ãƒˆï¼ˆå®šç¾©æ¸ˆã¿ã€è¦ç¢ºèªï¼‰ */
.practice-scenario    /* å®Ÿè·µã‚·ãƒŠãƒªã‚ª */
.clinical-case        /* è‡¨åºŠç—‡ä¾‹ */
.case-presentation    /* ç—‡ä¾‹æç¤º */
.clinical-pearls      /* è‡¨åºŠã®çœŸç  */
.clinical-significance /* è‡¨åºŠçš„æ„ç¾© */
.real-world-evidence  /* ãƒªã‚¢ãƒ«ãƒ¯ãƒ¼ãƒ«ãƒ‰ã‚¨ãƒ“ãƒ‡ãƒ³ã‚¹ */
.treatment-algorithm  /* æ²»ç™‚ã‚¢ãƒ«ã‚´ãƒªã‚ºãƒ  */
.decision-tree        /* æ„æ€æ±ºå®šãƒ„ãƒªãƒ¼ */
.protocol-based       /* ãƒ—ãƒ­ãƒˆã‚³ãƒ«ãƒ™ãƒ¼ã‚¹ */
```

### è­¦å‘Šãƒ»æ³¨æ„é–¢é€£ï¼ˆ15å€‹ï¼‰
```css
.warning-note         /* è­¦å‘Šæ³¨è¨˜ï¼ˆå®šç¾©æ¸ˆã¿ã€è¦ç¢ºèªï¼‰ */
.caution              /* æ³¨æ„ */
.caution-box          /* æ³¨æ„ãƒœãƒƒã‚¯ã‚¹ */
.danger               /* å±é™º */
.contraindication-box /* ç¦å¿Œãƒœãƒƒã‚¯ã‚¹ */
.drug-interaction-alert /* è–¬ç‰©ç›¸äº’ä½œç”¨ã‚¢ãƒ©ãƒ¼ãƒˆ */
.side-effect-warning  /* å‰¯ä½œç”¨è­¦å‘Š */
.monitoring-required  /* ãƒ¢ãƒ‹ã‚¿ãƒªãƒ³ã‚°å¿…è¦ */
.black-box-warning    /* ãƒ–ãƒ©ãƒƒã‚¯ãƒœãƒƒã‚¯ã‚¹è­¦å‘Š */
.safety-consideration /* å®‰å…¨æ€§è€ƒæ…®äº‹é … */
```

### ã‚¨ãƒ“ãƒ‡ãƒ³ã‚¹é–¢é€£ï¼ˆ15å€‹ï¼‰
```css
.clinical-evidence    /* è‡¨åºŠã‚¨ãƒ“ãƒ‡ãƒ³ã‚¹ï¼ˆå®šç¾©æ¸ˆã¿ã€è¦ç¢ºèªï¼‰ */
.evidence-based       /* ã‚¨ãƒ“ãƒ‡ãƒ³ã‚¹ãƒ™ãƒ¼ã‚¹ */
.evidence-summary     /* ã‚¨ãƒ“ãƒ‡ãƒ³ã‚¹ã‚µãƒãƒªãƒ¼ */
.study-reference      /* ç ”ç©¶å‚ç…§ */
.citation             /* å¼•ç”¨ */
.research-highlight   /* ç ”ç©¶ãƒã‚¤ãƒ©ã‚¤ãƒˆ */
.meta-analysis        /* ãƒ¡ã‚¿ã‚¢ãƒŠãƒªã‚·ã‚¹ */
.systematic-review    /* ã‚·ã‚¹ãƒ†ãƒãƒ†ã‚£ãƒƒã‚¯ãƒ¬ãƒ“ãƒ¥ãƒ¼ */
.clinical-trial       /* è‡¨åºŠè©¦é¨“ */
.outcome-data         /* ã‚¢ã‚¦ãƒˆã‚«ãƒ ãƒ‡ãƒ¼ã‚¿ */
```

### ã‚¤ãƒ³ã‚¿ãƒ©ã‚¯ãƒ†ã‚£ãƒ–è¦ç´ ï¼ˆ10å€‹ï¼‰
```css
.interactive-element  /* ã‚¤ãƒ³ã‚¿ãƒ©ã‚¯ãƒ†ã‚£ãƒ–è¦ç´  */
.expandable           /* å±•é–‹å¯èƒ½ */
.collapsible          /* æŠ˜ã‚ŠãŸãŸã¿å¯èƒ½ */
.toggle-content       /* ãƒˆã‚°ãƒ«ã‚³ãƒ³ãƒ†ãƒ³ãƒ„ */
.show-more            /* ã‚‚ã£ã¨è¦‹ã‚‹ */
.interactive-quiz     /* ã‚¤ãƒ³ã‚¿ãƒ©ã‚¯ãƒ†ã‚£ãƒ–ã‚¯ã‚¤ã‚º */
.knowledge-check      /* çŸ¥è­˜ãƒã‚§ãƒƒã‚¯ */
.self-assessment      /* è‡ªå·±è©•ä¾¡ */
.feedback-section     /* ãƒ•ã‚£ãƒ¼ãƒ‰ãƒãƒƒã‚¯ã‚»ã‚¯ã‚·ãƒ§ãƒ³ */
.progress-tracker     /* é€²æ—ãƒˆãƒ©ãƒƒã‚«ãƒ¼ */
```

---

## ğŸŸ¢ P2: ä¸­å„ªå…ˆã‚¯ãƒ©ã‚¹ï¼ˆ220å€‹ï¼‰

### è–¬ç†å­¦é–¢é€£ï¼ˆ60å€‹ï¼‰
```css
.molecular-discovery   /* åˆ†å­ãƒ¬ãƒ™ãƒ«ç™ºè¦‹ */
.cellular-effects      /* ç´°èƒãƒ¬ãƒ™ãƒ«åŠ¹æœ */
.metabolic-effects     /* ä»£è¬åŠ¹æœ */
.pharmacokinetics      /* è–¬ç‰©å‹•æ…‹ */
.pharmacodynamics      /* è–¬åŠ›å­¦ */
.mechanism-of-action   /* ä½œç”¨æ©Ÿåº */
.receptor-binding      /* å—å®¹ä½“çµåˆ */
.enzyme-inhibition     /* é…µç´ é˜»å®³ */
.signal-pathway        /* ã‚·ã‚°ãƒŠãƒ«çµŒè·¯ */
.drug-metabolism       /* è–¬ç‰©ä»£è¬ */
```

### è–¬åŠ¹ç¾¤ç‰¹åŒ–ï¼ˆ80å€‹ï¼‰
```css
/* å¾ªç’°å™¨ç³» */
.cardiovascular-effects /* å¿ƒè¡€ç®¡åŠ¹æœ */
.blood-pressure-control /* è¡€åœ§ã‚³ãƒ³ãƒˆãƒ­ãƒ¼ãƒ« */
.heart-rate-effects     /* å¿ƒæ‹æ•°åŠ¹æœ */
.vascular-protection    /* è¡€ç®¡ä¿è­· */
.anti-atherosclerotic   /* æŠ—å‹•è„ˆç¡¬åŒ– */

/* å†…åˆ†æ³Œç³» */
.glucose-lowering       /* è¡€ç³–é™ä¸‹ */
.insulin-sensitivity    /* ã‚¤ãƒ³ã‚¹ãƒªãƒ³æ„Ÿå—æ€§ */
.hormonal-effects       /* ãƒ›ãƒ«ãƒ¢ãƒ³åŠ¹æœ */
.metabolic-regulation   /* ä»£è¬èª¿ç¯€ */
.endocrine-modulation   /* å†…åˆ†æ³Œèª¿ç¯€ */

/* ä¸­æ¢ç¥çµŒç³» */
.neurotransmitter       /* ç¥çµŒä¼é”ç‰©è³ª */
.brain-penetration      /* è„³å†…ç§»è¡Œæ€§ */
.cognitive-effects      /* èªçŸ¥åŠ¹æœ */
.mood-stabilization     /* æ°—åˆ†å®‰å®šåŒ– */
.neurological-impact    /* ç¥çµŒå­¦çš„å½±éŸ¿ */
```

### æ¯”è¼ƒãƒ»é¸æŠé–¢é€£ï¼ˆ40å€‹ï¼‰
```css
.drug-comparison        /* è–¬å‰¤æ¯”è¼ƒ */
.selection-criteria     /* é¸æŠåŸºæº– */
.comparative-efficacy   /* æ¯”è¼ƒåŠ¹æœ */
.head-to-head          /* ç›´æ¥æ¯”è¼ƒ */
.superiority-data      /* å„ªè¶Šæ€§ãƒ‡ãƒ¼ã‚¿ */
.non-inferiority       /* éåŠ£æ€§ */
.therapeutic-equivalence /* æ²»ç™‚åŒç­‰æ€§ */
.cost-effectiveness    /* è²»ç”¨å¯¾åŠ¹æœ */
.clinical-preference   /* è‡¨åºŠçš„é¸å¥½ */
.guideline-position    /* ã‚¬ã‚¤ãƒ‰ãƒ©ã‚¤ãƒ³ä½ç½®ã¥ã‘ */
```

### æ‚£è€…ç®¡ç†é–¢é€£ï¼ˆ40å€‹ï¼‰
```css
.patient-monitoring    /* æ‚£è€…ãƒ¢ãƒ‹ã‚¿ãƒªãƒ³ã‚° */
.follow-up-schedule    /* ãƒ•ã‚©ãƒ­ãƒ¼ã‚¢ãƒƒãƒ—ã‚¹ã‚±ã‚¸ãƒ¥ãƒ¼ãƒ« */
.titration-guide       /* ç”¨é‡èª¿ç¯€ã‚¬ã‚¤ãƒ‰ */
.adherence-tips        /* ã‚¢ãƒ‰ãƒ’ã‚¢ãƒ©ãƒ³ã‚¹ã®ã‚³ãƒ„ */
.patient-education     /* æ‚£è€…æ•™è‚² */
.counseling-points     /* ã‚«ã‚¦ãƒ³ã‚»ãƒªãƒ³ã‚°ãƒã‚¤ãƒ³ãƒˆ */
.lifestyle-modification /* ç”Ÿæ´»ç¿’æ…£æ”¹å–„ */
.diet-considerations   /* é£Ÿäº‹è€ƒæ…®äº‹é … */
.exercise-guidance     /* é‹å‹•æŒ‡å° */
.special-populations   /* ç‰¹åˆ¥ãªé›†å›£ */
```

---

## ğŸ”µ P3: ä½å„ªå…ˆã‚¯ãƒ©ã‚¹ï¼ˆ268å€‹ï¼‰

### è¦–è¦šçš„è£…é£¾ï¼ˆ80å€‹ï¼‰
```css
.decorative-border     /* è£…é£¾çš„ãƒœãƒ¼ãƒ€ãƒ¼ */
.background-pattern    /* èƒŒæ™¯ãƒ‘ã‚¿ãƒ¼ãƒ³ */
.shadow-effect         /* å½±åŠ¹æœ */
.gradient-overlay      /* ã‚°ãƒ©ãƒ‡ãƒ¼ã‚·ãƒ§ãƒ³ã‚ªãƒ¼ãƒãƒ¼ãƒ¬ã‚¤ */
.visual-separator      /* è¦–è¦šçš„ã‚»ãƒ‘ãƒ¬ãƒ¼ã‚¿ãƒ¼ */
.ornamental-element    /* è£…é£¾çš„è¦ç´  */
.aesthetic-enhancement /* ç¾çš„å¼·åŒ– */
.style-variation       /* ã‚¹ã‚¿ã‚¤ãƒ«ãƒãƒªã‚¨ãƒ¼ã‚·ãƒ§ãƒ³ */
.theme-accent          /* ãƒ†ãƒ¼ãƒã‚¢ã‚¯ã‚»ãƒ³ãƒˆ */
.design-flourish       /* ãƒ‡ã‚¶ã‚¤ãƒ³ã®è£…é£¾ */
```

### è£œåŠ©çš„UIè¦ç´ ï¼ˆ88å€‹ï¼‰
```css
.tooltip-container     /* ãƒ„ãƒ¼ãƒ«ãƒãƒƒãƒ—ã‚³ãƒ³ãƒ†ãƒŠ */
.hover-effect          /* ãƒ›ãƒãƒ¼åŠ¹æœ */
.transition-smooth     /* ã‚¹ãƒ ãƒ¼ã‚ºãƒˆãƒ©ãƒ³ã‚¸ã‚·ãƒ§ãƒ³ */
.animation-subtle      /* æ§ãˆã‚ãªã‚¢ãƒ‹ãƒ¡ãƒ¼ã‚·ãƒ§ãƒ³ */
.micro-interaction     /* ãƒã‚¤ã‚¯ãƒ­ã‚¤ãƒ³ã‚¿ãƒ©ã‚¯ã‚·ãƒ§ãƒ³ */
.visual-feedback       /* è¦–è¦šçš„ãƒ•ã‚£ãƒ¼ãƒ‰ãƒãƒƒã‚¯ */
.state-indicator       /* çŠ¶æ…‹ã‚¤ãƒ³ã‚¸ã‚±ãƒ¼ã‚¿ãƒ¼ */
.progress-visual       /* é€²æ—è¦–è¦šåŒ– */
.loading-state         /* ãƒ­ãƒ¼ãƒ‡ã‚£ãƒ³ã‚°çŠ¶æ…‹ */
.completion-badge      /* å®Œäº†ãƒãƒƒã‚¸ */
```

### è©³ç´°ãƒ‡ãƒ¼ã‚¿è¡¨ç¤ºï¼ˆ100å€‹ï¼‰
```css
.data-table            /* ãƒ‡ãƒ¼ã‚¿ãƒ†ãƒ¼ãƒ–ãƒ« */
.statistical-chart     /* çµ±è¨ˆãƒãƒ£ãƒ¼ãƒˆ */
.graph-container       /* ã‚°ãƒ©ãƒ•ã‚³ãƒ³ãƒ†ãƒŠ */
.timeline-visual       /* ã‚¿ã‚¤ãƒ ãƒ©ã‚¤ãƒ³è¦–è¦šåŒ– */
.infographic-element   /* ã‚¤ãƒ³ãƒ•ã‚©ã‚°ãƒ©ãƒ•ã‚£ãƒƒã‚¯è¦ç´  */
.data-visualization    /* ãƒ‡ãƒ¼ã‚¿å¯è¦–åŒ– */
.metric-display        /* ãƒ¡ãƒˆãƒªã‚¯ã‚¹è¡¨ç¤º */
.percentage-bar        /* ãƒ‘ãƒ¼ã‚»ãƒ³ãƒ†ãƒ¼ã‚¸ãƒãƒ¼ */
.comparison-chart      /* æ¯”è¼ƒãƒãƒ£ãƒ¼ãƒˆ */
.trend-indicator       /* ãƒˆãƒ¬ãƒ³ãƒ‰ã‚¤ãƒ³ã‚¸ã‚±ãƒ¼ã‚¿ãƒ¼ */
```

---

## ğŸ”§ å®Ÿè£…æˆ¦ç•¥

### P0å®Ÿè£…æ–¹é‡ï¼ˆ30åˆ†ï¼‰
1. **æ§‹é€ ã®å®‰å®šæ€§ã‚’æœ€å„ªå…ˆ**
2. **æœ€å°é™ã®ã‚¹ã‚¿ã‚¤ãƒ«ã§æ©Ÿèƒ½ç¢ºä¿**
3. **æ—¢å­˜ã®CSSå¤‰æ•°ã‚’æœ€å¤§æ´»ç”¨**

### P1å®Ÿè£…æ–¹é‡ï¼ˆ120åˆ†ï¼‰
1. **3æ®µéšå­¦ç¿’ã®è¦–è¦šçš„å·®åˆ¥åŒ–**
2. **è‡¨åºŠçš„é‡è¦æ€§ã®å¼·èª¿**
3. **ã‚¤ãƒ³ã‚¿ãƒ©ã‚¯ãƒ†ã‚£ãƒ–æ€§ã®ç¢ºä¿**

### P2å®Ÿè£…æ–¹é‡ï¼ˆ90åˆ†ï¼‰
1. **è–¬åŠ¹ç¾¤ã”ã¨ã®ãƒãƒƒãƒå‡¦ç†**
2. **å…±é€šãƒ‘ã‚¿ãƒ¼ãƒ³ã®æŠ½å‡ºã¨å†åˆ©ç”¨**
3. **ç§‘å­¦çš„æ­£ç¢ºæ€§ã®ç¶­æŒ**

### P3å®Ÿè£…æ–¹é‡ï¼ˆ90åˆ†ï¼‰
1. **è‡ªå‹•åŒ–å¯èƒ½ãªéƒ¨åˆ†ã®ç‰¹å®š**
2. **æ—¢å­˜ã‚¹ã‚¿ã‚¤ãƒ«ã‹ã‚‰ã®æµç”¨**
3. **æœ€çµ‚çš„ãªæ´—ç·´**

---

## ğŸ“ æ¬¡ã®ã‚¹ãƒ†ãƒƒãƒ—

1. **P0ã‚¯ãƒ©ã‚¹ã®CSSå®šç¾©é–‹å§‹**
2. **å„ã‚¯ãƒ©ã‚¹ã®å…·ä½“çš„ãªã‚¹ã‚¿ã‚¤ãƒ«å±æ€§æ±ºå®š**
3. **ver2-unified.cssã¸ã®æ®µéšçš„è¿½åŠ **

---

**åˆ†é¡å®Œäº†æ™‚åˆ»**: 2025-07-02 17:38